Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Total Current Liabilities data on file, last reported at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 19.62% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (down 19.62% YoY), and the FY2025 full-year result was $22.9 million, down 38.57% from the prior year.
• Total Current Liabilities retreated to $21.2 million in Q1 2026, from $22.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $100.0 million in Q4 2023 to a low of $18.7 million in Q1 2022.
• A 5-year average of $36.0 million and a median of $33.5 million in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 178.75% in 2023 and tumbled 62.67% in 2024, its largest moves.
• Tracing BNGO's Total Current Liabilities over 5 years: stood at $35.9 million in 2022, then surged by 178.75% to $100.0 million in 2023, then plunged by 62.67% to $37.3 million in 2024, then sank by 38.57% to $22.9 million in 2025, then fell by 7.47% to $21.2 million in 2026.
• Business Quant data shows BNGO's Total Current Liabilities at $21.2 million in Q1 2026, $22.9 million in Q4 2025, and $23.0 million in Q3 2025.